Bladex Structures USD 1.0 Billion Loan for the Republic of Panama

BLADEX, INC. (BLX) furnished an SEC Form 6-K — earnings release. o SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BLADEX, INC. (Registrant) Date: July 28, 2026 By: /s/ Annette van Hoorde de Solís

Bladex, Inc. (NYSE: BLX) reported 2Q26 net profit of $66.5 million, or $1.77 per share, up 4% year over year, and $122.8 million for 6M26. Net interest income rose to $73.3 million in 2Q26. The board approved a $0.6875 quarterly dividend. S&P upgraded ratings to BBB+ with Stable outlook.

Boralex said it received final court approval from Québec’s Superior Court for its section 192 plan of arrangement with BIF Thunder Holdings Inc., jointly owned by Brookfield Infrastructure Fund V (and/or affiliates) and Caisse de dépôt et placement du Québec. Shareholders approved on June 4, 2026. Closing remains subject to customary conditions and key regulatory approvals, with completion expected in Q4 2026.

Boralex said shareholders approved its acquisition arrangement with Brookfield and La Caisse at a June 4, 2026 meeting. The statutory plan covers all Class A shares at $37.25 cash per share, approved by 99.86% of votes cast (excluding La Caisse for the minority vote). Court and regulatory approvals are still required; the final order hearing is June 5, with completion expected in Q4 2026.

Oracle increased its fiscal 2026 restructuring plan by $700M, totaling $2.8B, due to AI integration and layoffs. The company reported strong revenue growth, with cloud services up 30% to $19.3B, but capital expenditures surged to $28.5B, resulting in negative free cash flow. Oracle's stock fell 5% after the announcement.

Axon (AXON) shares fell 8.7% after announcing a $1.0 billion convertible note offering, with an option for an additional $150 million. The company plans to use proceeds for capped call transactions and general corporate purposes. Axon's stock is down 21% year-to-date, trading 42.7% below its 52-week high.